-
公开(公告)号：US09090712B2
公开(公告)日：2015-07-28
申请号：US12536975
申请日：2009-08-06
Applicant: Ingegerd Hellstrom , Jeffrey A. Ledbetter , Martha Hayden-Ledbetter
Inventor： Ingegerd Hellstrom , Jeffrey A. Ledbetter , Martha Hayden-Ledbetter
IPC: C07K14/435 , C07K19/00 , C07K14/81 , C07K16/18 , C07K16/30 , C07K16/40 , G01N33/574 , G01N33/53 , A61K39/00
CPC classification number: G01N33/57449 , A61K2039/505 , C07K14/811 , C07K16/18 , C07K16/30 , C07K16/3069 , C07K16/40 , C07K2319/00 , C07K2319/30 , G01N33/57488 , G01N2333/705
Abstract: The invention is directed to compositions and methods for the detection of a malignant condition, and relates to the discovery of soluble and cell surface forms of HE4a polypeptides, including HE4a that is overexpressed in ovarian carcinomas. In particular the invention provides a nucleic acid sequence encoding HE4a, and also provides a method of screening for the presence of a malignant condition in a subject by detecting reactivity of an antibody specific for a HE4a polypeptide with a molecule naturally occurring in soluble and/or cell surface form in a sample from such a subject, and by hybridization screening using an HE4a nucleotide sequence, as well as other related advantages.
-
公开(公告)号：US20090104684A1
公开(公告)日：2009-04-23
申请号：US11890896
申请日：2007-08-08
Applicant: Michel Schummer , INGEGERD HELLSTROM , Karl Erik Hellstrom , JEFFREY A. LEDBETTER , MARTHA HAYDEN-LEDBETTER
Inventor： Michel Schummer , INGEGERD HELLSTROM , Karl Erik Hellstrom , JEFFREY A. LEDBETTER , MARTHA HAYDEN-LEDBETTER
CPC classification number: G01N33/57449 , A61K2039/505 , C07K14/811 , C07K16/18 , C07K16/30 , C07K16/3069 , C07K16/40 , C07K2319/00 , C07K2319/30 , G01N33/57488 , G01N2333/705
Abstract: The invention is directed to compositions and methods for the detection of a malignant condition, and relates to the discovery of soluble and cell surface forms of HE4a polypeptides, including HE4a that is overexpressed in ovarian carcinomas. In particular the invention provides a nucleic acid sequence encoding HE4a, and also provides a method of screening for the presence of a malignant condition in a subject by detecting reactivity of an antibody specific for a HE4a polypeptide with a molecule naturally occurring in soluble and/or cell surface form in a sample from such a subject, and by hybridization screening using an HE4a nucleotide sequence, as well as other related advantages.
Abstract translation: 本发明涉及用于检测恶性病症的组合物和方法，并且涉及HE4a多肽的可溶性和细胞表面形式的发现，包括在卵巢癌中过表达的HE4a。 特别地，本发明提供了编码HE4a的核酸序列，并且还提供了通过检测对具有天然存在于可溶性和/或可溶性的分子的HE4a多肽的特异性抗体的反应性来筛选受试者中恶性病症的存在的方法。 来自这样的受试者的样品中的细胞表面形式，以及使用HE4a核苷酸序列的杂交筛选以及其它相关优点。
-
公开(公告)号：US07270960B2
公开(公告)日：2007-09-18
申请号：US10233150
申请日：2002-08-28
Applicant: Ingegerd Hellstrom , Jeffrey A. Ledbetter , Martha Hayden-Ledbetter
Inventor： Ingegerd Hellstrom , Jeffrey A. Ledbetter , Martha Hayden-Ledbetter
CPC classification number: G01N33/57449 , A61K2039/505 , C07K14/811 , C07K16/18 , C07K16/30 , C07K16/3069 , C07K16/40 , C07K2319/00 , C07K2319/30 , G01N33/57488 , G01N2333/705
Abstract: The invention is directed to compositions and methods for the detection of a malignant condition, and relates to the discovery of soluble and cell surface forms of HE4a polypeptides, including HE4a that is overexpressed in ovarian carcinomas. In particular the invention provides a nucleic acid sequence encoding HE4a, and also provides a method of screening for the presence of a malignant condition in a subject by detecting reactivity of an antibody specific for a HE4a polypeptide with a molecule naturally occurring in soluble and/or cell surface form in a sample from such a subject, and by hybridization screening using an HE4a nucleotide sequence, as well as other related advantages.
Abstract translation: 本发明涉及用于检测恶性病症的组合物和方法，并且涉及HE4a多肽的可溶性和细胞表面形式的发现，包括在卵巢癌中过表达的HE4a。 特别地，本发明提供了编码HE4a的核酸序列，并且还提供了通过检测对具有天然存在于可溶性和/或可溶性的分子的HE4a多肽的特异性抗体的反应性来筛选受试者中恶性病症的存在的方法。 来自这样的受试者的样品中的细胞表面形式，以及使用HE4a核苷酸序列的杂交筛选以及其它相关优点。
-
4.发明授权Tumor associated antigen recognized by the murine monoclonal antibody L6, its oligonucleotide sequence and methods for their use 失效由鼠单克隆抗体L6识别的肿瘤相关抗原，其寡核苷酸序列及其使用方法
公开(公告)号：US5597707A
公开(公告)日：1997-01-28
申请号：US48700
申请日：1993-04-15
Applicant: John Marken , Gary L. Schieven , Ingegerd Hellstrom , Karl E. Hellstrom , Alejandro Aruffo
Inventor： John Marken , Gary L. Schieven , Ingegerd Hellstrom , Karl E. Hellstrom , Alejandro Aruffo
CPC classification number: G01N33/57492 , C07K14/4748 , A61K38/00 , G01N2333/705
Abstract: The present invention definitively identifies and characterizes the tumor-associated antigen immunologically recognized by the murine monoclonal antibody L6. Further, the present invention provides the nucleotide sequence which encodes the L6 antigen. Various diagnostic, prophylactic and therapeutic methods comprising the L6 antigen and the nucleotide sequence which encodes the L6 antigen are also provided.
Abstract translation: 本发明明确地鉴定和表征由鼠单克隆抗体L6免疫识别的肿瘤相关抗原。 此外，本发明提供编码L6抗原的核苷酸序列。 还提供了包含L6抗原和编码L6抗原的核苷酸序列的各种诊断，预防和治疗方法。
-
公开(公告)号：US5242824A
公开(公告)日：1993-09-07
申请号：US443696
申请日：1989-11-29
Applicant: Ingegerd Hellstrom , Karl E. Hellstrom
Inventor： Ingegerd Hellstrom , Karl E. Hellstrom
IPC: G01N33/574 , A61K38/00 , A61K39/395 , A61K45/00 , A61K47/48 , A61K49/00 , A61K51/00 , A61P35/00 , C07K14/00 , C07K14/52 , C07K16/00 , C07K16/30 , C07K16/46 , C07K19/00 , C12N5/10 , C12N15/02 , C12P21/08 , C12R1/91 , G01N33/577
CPC classification number: C07K16/468 , A61K47/48569 , A61K47/48669 , A61K49/0004 , C07K16/30 , A61K38/00 , C07K2317/732 , C07K2317/77
Abstract: The present invention relates to a novel monoclonal antibody reactive with human carcinoma cells. More particularly, the antibody of the invention is a monoclonal antibody reactive with a glycolipid cell membrane antigen on the surface of human carcinomas. The antibody displays a high degree of selectivity for carcinoma cells, showing a low degree of reactivity with certain normal human cells and no detectable reactivity with other types of tumors such as lymphomas, sarcomas or melanomas. In addition, the antibody of the invention is capable of internalizing within the carcinoma cells to which it binds and is therefore particularly useful for therapeutic applications, for example, as the antibody component of antibody-drug or antibody-toxin conjugates.
-
Patent Agency Ranking6.发明授权Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy 失效与生物活性抗肿瘤抗体和化疗相结合的协同肿瘤治疗
公开(公告)号：US5165922A
公开(公告)日：1992-11-24
申请号：US527227
申请日：1990-05-22
Applicant: Karl E. Hellstrom , Ingegerd Hellstrom , Gary E. Goodman
Inventor： Karl E. Hellstrom , Ingegerd Hellstrom , Gary E. Goodman
CPC classification number: C07K16/30 , A61K39/395 , A61K45/06 , A61K47/48569 , A61K38/00
Abstract: The present invention relates to the use of combinations of antibody therapy and chemotherapy in the treatment of malignant disease. More particularly, the invention relates to novel methods of treating patients who have malignant disease and who have shown an unresponsiveness to treatment with standard chemotherapy regimens by administering to those patients (i) an antibody that binds to the malignant cells of the patient and (ii) a chemotherapeutic agent. According to particular embodiments of the invention, anti-glycolipid antibodies are administered to patients who are subsequently treated with standard chemotherapy regimens.
Abstract translation: 本发明涉及抗体治疗和化疗联合治疗恶性疾病的用途。 更具体地说，本发明涉及治疗患有恶性疾病的患者的新方法，并且通过给予那些患者（i）与患者的恶性细胞结合的抗体，以及（ii）与标准化疗方案治疗无关 ）化疗剂。 根据本发明的具体实施方案，将抗糖脂抗体施用于随后用标准化疗方案治疗的患者。
-
公开(公告)号：US5091178A
公开(公告)日：1992-02-25
申请号：US473137
申请日：1990-01-30
Applicant: Karl E. Hellstrom , Ingegerd Hellstrom
Inventor： Karl E. Hellstrom , Ingegerd Hellstrom
CPC classification number: C07K16/30 , A61K38/00 , C07K2317/73 , C07K2317/732 , C07K2317/734 , Y10S424/804 , Y10S530/808 , Y10S530/828 , Y10S530/861
Abstract: A method for identifying and using antibodies which are directed against tumor-associated glycolipid antigens and which are capable of activating serum complement or antibody dependent cellular cytotoxicity. These antibodies find use in the therapy of tumors. Administration of the antibodies results in lysis of the tumor cells in vivo.
Abstract translation: 用于鉴定和使用针对肿瘤相关糖脂抗原的能够激活血清补体或抗体依赖性细胞毒性的抗体的方法。 这些抗体可用于治疗肿瘤。 抗体的施用导致体内肿瘤细胞裂解。
-
公开(公告)号：US4918164A
公开(公告)日：1990-04-17
申请号：US116802
申请日：1987-11-04
Applicant: Ingegerd Hellstrom , Karl E. Hellstrom , Maria S. Kahn
Inventor： Ingegerd Hellstrom , Karl E. Hellstrom , Maria S. Kahn
CPC classification number: G01N33/686 , C07K16/2809 , C07K16/30 , C07K16/4266 , G01N33/57423 , G01N33/5743 , G01N33/57476 , G01N33/57488 , A61K38/00 , A61K39/00 , C07K2317/732 , C07K2317/734 , Y10S530/806 , Y10S530/808 , Y10S530/828 , Y10S530/866
Abstract: The present invention relates to methods which utilize anti-idiotypic antibodies, or fragments thereof, for tumor immunotherapy or immunoprophylaxis. Monoclonal anti-idiotypic antibodies which recognize an idiotype present on a second antibody or on a T lymphocyte or on an immune suppressor factor which is directed against a defined tumor antigen, can be used for immunization against a tumor, for immune anti-tumor activation or inhibition of suppression, or for in vitro activation of lymphocytes to be used in adoptive immunotherapy. The anti-idiotypic antibodies, or fragments thereof, can also be used to monitor anti-antibody induction in patients undergoing passive immunization to a tumor antigen by administration of anti-tumor antibody. In another embodiment, administration of T lymphocytes which express an idiotype directed against a defined tumor antigen can be used to transfer delayed-type hypersensitivity to the tumor. In another method of the invention, the induction of anti-idiotypic antibodies in vivo by administration of anti-tumor antibody or immune cells or factors exhibiting an anti-tumor idiotype can be therapeutically valuable.
Abstract translation: 本发明涉及利用抗独特型抗体或其片段用于肿瘤免疫治疗或免疫预防的方法。 识别存在于第二抗体或T淋巴细胞上的独特型单克隆抗独特型抗体或针对定义的肿瘤抗原的免疫抑制因子的单克隆抗独特型抗体可用于针对肿瘤的免疫，用于免疫抗肿瘤活化或 抑制或抑制用于过继免疫治疗的淋巴细胞的体外活化。 抗独特型抗体或其片段也可用于通过施用抗肿瘤抗体来监测对肿瘤抗原进行被动免疫的患者的抗 - 抗体诱导。 在另一个实施方案中，可以使用表达针对定义的肿瘤抗原的独特型的T淋巴细胞的施用来将延迟型超敏反应转移至肿瘤。 在本发明的另一种方法中，通过施用抗肿瘤抗体或免疫细胞或显示抗肿瘤独特型的因子在体内诱导抗独特型抗体是有治疗价值的。
-
公开(公告)号：US06734172B2
公开(公告)日：2004-05-11
申请号：US09441411
申请日：1999-11-16
Applicant: Nathalie B. Scholler , Mary L. Disis , Ingegerd Hellstrom , Karl Erik Hellstrom
Inventor： Nathalie B. Scholler , Mary L. Disis , Ingegerd Hellstrom , Karl Erik Hellstrom
IPC: A01N4304
CPC classification number: A61K39/0011 , A61K2039/53 , A61K2039/55516 , C07K14/705
Abstract: The invention provides compositions and methods directed to cell surface receptor antigen specific vaccines. More specifically, vaccines are provided that induce or enhance host antibody titers specific for cell surface receptor antigens and that include recombinant expression constructs containing nucleic acids encoding a target cell surface receptor antigen and one or more immune response altering molecules, or the expressed products themselves.
Abstract translation: 本发明提供了针对细胞表面受体抗原特异性疫苗的组合物和方法。 更具体地，提供了诱导或增强对细胞表面受体抗原特异性的宿主抗体滴度的疫苗，并且包括含有编码靶细胞表面受体抗原和一种或多种免疫应答改变分子的核酸或表达产物本身的重组表达构建体。
-
公开(公告)号：US5811098A
公开(公告)日：1998-09-22
申请号：US484438
申请日：1995-06-07
Applicant: Gregory D. Plowman , Jean-Michel Culouscou , Mohammed Shoyab , Clay B. Siegall , Ingegerd Hellstrom , Karl E. Hellstrom
Inventor： Gregory D. Plowman , Jean-Michel Culouscou , Mohammed Shoyab , Clay B. Siegall , Ingegerd Hellstrom , Karl E. Hellstrom
IPC: A61K47/48 , C07K14/475 , C07K16/28 , A61K39/00
CPC classification number: C07K14/4756 , A61K47/48561 , C07K16/2863 , G01N2333/4756
Abstract: The molecular cloning, expression, and biological characteristics of a novel receptor tyrosine kinase related to the epidermal growth factor receptor, termed HER4/p180.sup.erbB4, are described. Antibodies to HER4 are disclosed. A HER4 ligand capable of inducing cellular differentiation of breast cancer cells is also disclosed. In view of the expression of HER4 in several human cancers and in certain tissues of neuronal and muscular origin, various diagnostic and therapeutic uses of HER4-derived and HER4-related biological compositions are provided.
Abstract translation: 描述了与表皮生长因子受体相关的新受体酪氨酸激酶的分子克隆，表达和生物学特征，称为HER4 / p180erbB4。 公开了HER4抗体。 还公开了能够诱导乳腺癌细胞的细胞分化的HER4配体。 鉴于HER4在几种人类癌症和神经元和肌肉起源的某些组织中的表达，提供了HER4衍生和HER4相关生物组合物的各种诊断和治疗用途。
-
-
-
-
-
-
-
-
-
Search Results
39
records
(took 0.028 seconds)
